Skip to content

Matthew L. Posard, Director at Halozyme Therapeutics, sold HALO on Oct 1, 2026

Data as of Oct 16

▼ SELL$11K100 shares at $110.04Matthew L. Posard DirectorHALO Halozyme Therapeutics, Inc.
Watch HALO
Traded
Oct 1, 2026
Disclosed
Oct 2, 2026
Filed
1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Matthew L. Posard, Director at Halozyme Therapeutics, sold HALO on Oct 1, 2026TRADEDDISCLOSED
HALOSimilar stocks (XLV — its sector index fund), rebased to HALO's price on the disclosure day
HALO since disclosure
+10.9%
after the sale
Similar stocks (XLV) since disclosure
+6.3%
XLV — its sector index fund

Change in closing price from Oct 2, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLMatthew L. Posard DirectorHALO Halozyme Therapeutics, Inc.$121Kdisclosed Oct 2 · filed 1 day after the trade
  2. ▼ SELLMatthew L. Posard DirectorHALO Halozyme Therapeutics, Inc.$358Kdisclosed Oct 2 · filed 1 day after the trade
  3. ▼ SELLMatthew L. Posard DirectorHALO Halozyme Therapeutics, Inc.$78.2Kdisclosed Oct 2 · filed 1 day after the trade

See every trade on HALO →